The wide spread development of heart transplantation provided the stimulus for research and development in the field of mechanical circulatory support. Success in the development of mechanical assist support for heart failure patients further highlighted the growing worldwide shortage of donor organs.
The goal of early research was the development of the total artificial heart, capable of sustaining the functions of left and right ventricles. Research efforts shifted to the development of a left ventricular device due to the poor performance of first generation total artificial hearts as well as the emergence of clinical evidence suggesting successful treatment of heart failure by means of mechanical assistance of the left ventricle only (1) .
Development of the Left Ventricular Assist System (LVAS) Novacor N100 began 25 years ago and, after a long experimental phase (2) (3) (4) , the first clinical implant was performed in 1984 (5) . In 1994, the Novacor LVAS received commercial approval in Europe (6) and by 1998, more than 400 European heart failure patients have benefitted from the Novacor LVAS.
Present world experience
By the end of 1997, 820 patients had received the Novacor LVAS throghout the world. The average age of treated patients is 47 years, average weight 79 kg, and body surface 1.9 sqm. The average duration of implant has been 89 days. The majority of patients were transplant candidates. 426 were transplanted, with 88% early survival. A total of 23 patients were weaned from the device after demonstrated sufficient myocardial recovery. In an average follow-up of 2.8 years late deaths were 12 (3%). A total of 57% of the implants were carried out in Europe, in Centres qualified for heart-transplant: in Italy five Institutions have been involved in the programme, included among which is our Institute.
Indications
There does not exist at the moment a sufficient body of experience to formulate criteria and classifications that are based on uniform patient-population studies that are suffi-ciently large. The Novacor LVAS was originally designed for long term application. While average length of stay on the device is approximately 90 days, 20 European patients have been on the Novacor system for 1 year or longer. This group is composed of bridge, recovery and long term device patients.
Elective indication is represented by cardiomyopathies and mostly by dilatative cardiomyopathies that reach such a clinical level of gravity that mortality risk at 6 months exceeds 50%. The ideal candidate must not have reached conditions of gravity that have induced serious multi-organ failure. The need for mechanical ventilation, hyperbilirubinemia, and oliguria in fact represent important risk factors which, if associated at an advanced age (more than 45 years), may, in fact, represent a complete contraindication.
It is current opinion that the indication for Novacor is constituted by those hemodynamic and clinical conditions that represent accepted criteria for inscription in a transplant list, and when, at the same time, no availability is made for obtaining a transplant heart within useful time. An important and primary contemporary pathology of the right ventricle clearly represents an absolute contraindication, just as the presence of a pathology of the aortic valve or the previous implant of an aortic prosthesis. A particular indication that may demand Novacor implant in cardiomyopathies is represented by the evidence of refractory and recurrent tachyarrhythmias.
RESULTS
A total of 57% of the implants were carried out in Europe through December 1997, and now number 409. This group of patients obtained better results, with a final success rate of 68%.
The most important risk factors that emerged in the course of clinical experience are an age over 45 years, a prolonged pre-operational stay spent in Intensive Care Unit with maximal dosages of inotropic drugs or mechanical ventilation, creatine values above 3 mg, fever and leucocytosis, high pulmonary vascular resistance, atrial arrhythmia, previous cardiac arrest, aortic contrapulsation or previous cardio-thoracic surgery.
The worst results in European experience were obtained in the emergency indications, mainly represented by post-cardiotomy failure and by post ischemic cardiogenic shock. The few implants performed in these conditions have in fact witnessed the prevalence of failures over successes with absolutely prohibitive results in post-cardiotomy implants, for which an 87% mortality rate has been observed.
Other indications for Novacor in the European experience have been ischemic cardiopathy (77 implants with 43% successes), myocardites (13 implants with 69% successes), and one successful case of complex congenital cardiopathy. The total European experience shows that a patient with end stage refractory dilatative cardiopathy bridged to transplant with the Novacor assist device has a 70% success-probability rate (7) .
Reference has been previously made to the fact that over the years alternative indications have become outlined for Novacor that is no longer seen as a bridge to transplant, as much as a long-term support or as temporary aid for a decompensated heart (8) (9) . Novacor's reliability as long-term support has been consolidating itself with time, and also through the continuous improvements that have taken place in technology, making the assistance device e §sier to wear.
Still today, however, no pre-implant criteria exist that permit one to declare with any certainty or with a degree of high probability whether that particular implant will have the significance as a bridge to transplant or as a definitive aid. Certainly in the course of the years the numbers of patients who in the European case studies left hospital wearing the Novacor has increased significantly, so that in 1993 they were 2, 13 in 1994, 27 in 1995, that finally became 41 in 1996. Currently, there are four patients throughout the world who have survived more than two years, thanks to Novacor.
Enjoying a similar increase has been the experience related to the Novacor application as a bridge to recovery. The first experience in fact dates back only to 8 June 1995 (10), since then 23 patients have been saved thanks to the treatment, and 22 of these are still alive and have returned to a normal life. The average duration of the implant has been reasonably long, varying between 7 and 8 months. Most of the patients that made up this case study were affected by dilatative cardiopathy, and one of them had undergone a previous ventriculoplastic operation in accordance with Batista. Contrary to expectations only a minority of this group was affected by myocarditis.
Management of the patient
Novacor implantation is to be considered a major surgical operation that in most centres is performed in extracoporal circulation, with a phase of aortic clamping either longer or shorter according to the technique used (11) (12) (13) (14) . The implant makes provision for two dacron tubular prostheses that connect the device respectively to the apex of the left ventricle and to the ascending aorta, two valvular prostheses at the entry to and exit from the mechanical ventricle respectively, (porcine bioprostheses), as well as an electrical connection cable coming out of the skin of the patient to join the power and control unit. Thus potential risks of infection, thromboembolism and hemorrhage exist. The surgical technique must be as accurate as possible in reducing the potentiality of these risks: careful hemostasis, rigorous respect for sterility, the anatomic reconstruction of the dissection plans, all represent essential surgical steps.
Despite this, preventive antibiotic, anti-aggregating agents, and anticoagulants make up the pillars of the treatment of these patients. Related to the presence of thromboembolic risk numerous are the protocols that have been adopted, all of which make provision for various phases, beginning prior to implant and subsequent modifications at the early and late post-operative stage. Main drugs are dicumarolics, aspirin, ticlopidine, dipyridamole and, during surgery, heparin.
The removal of Novacor at transplantation or after a successful recovery of the native heart represents a demanding surgical performance due to formation of adhesions and pump encapsulation after insertion (15) . Use of a goretex patch for reconstructing the pericardial cavity would be useful in reducing the complexity of pump removal. In conclusion, the mechanical assistance of the left ventricle nowadays represents a technology in evolution, that is still a long way to reach the stage of a longterm reliable aid. And it is certainly a reliable aid as a bridge when implanted with the right indications, and excellent premises exist for maintaining that in a non-distant future one will be able to face an easy and favourable survival by wearing a Novacor LVAS.
